Document Detail


Chemotherapeutic agents targeting the tubulin cytoskeleton modify LPS-induced cytokine secretion by dendritic cells and increase antigen presentation.
MedLine Citation:
PMID:  20386470     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recent studies support the idea that certain chemotherapeutic agents do not act only by cytotoxicity, but also have immunomodulatory activity. Because of their role in mitosis chemotherapeutic agents targeting microtubules are widely used, and this study determined the outcome of disturbing tubulin cytoskeleton dynamics on human dendritic cell function. Dendritic cells (DCs) play a major role in the generation of the adaptive immune response owing to their capacity for antigen presentation leading to T lymphocyte activation and differentiation and there is compelling evidence for their contribution to the antitumoral immune response. Two agents that target the tubulin cytoskeleton were used, taxol and colchicine, and a brief pretreatment with either increased antigen presentation by DCs independently of significant phenotypic change, cell death, or cytokine production. Although taxol and colchicine use different mechanisms to disrupt microtubules, NF-kappabeta was activated by either. We therefore determined whether the cytokine secretion profile in response to lipopolysaccharide (LPS) was modified. LPS stimulation of DCs induced IL-10, IL-12p70, TNFalpha and IL-1beta secretion, and taxol pretreatment modified this response by down-regulating IL-1beta secretion whereas colchicine induced a proinflammatory cytokine profile with reduced IL-10 and increased IL-12p70 and TNFalpha secretion. Taken together, these data reveal new immunomodulatory strategies of microtubule disrupting agents in dendritic cells, that of modifying the cytokine response to LPS and that of increasing T lymphocyte activation without induction of inflammatory cytokine secretion by dendritic cells.
Authors:
Viviana Marin-Esteban; Dominique Charron; Catherine Gelin; Nuala Mooney
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of immunotherapy (Hagerstown, Md. : 1997)     Volume:  33     ISSN:  1537-4513     ISO Abbreviation:  J. Immunother.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-28     Completed Date:  2010-09-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9706083     Medline TA:  J Immunother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  364-70     Citation Subset:  IM    
Affiliation:
Institut Universitaire d'Hématologie, Université Paris-Diderot-Paris 7, INSERM Unité 940, Hématologie, Immunologie, Cibles thérapeutiques, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antigen Presentation / drug effects
Antineoplastic Agents / pharmacology*
Cells, Cultured
Colchicine / pharmacology*
Cytokines / secretion
Cytoskeleton / drug effects*
Dendritic Cells / drug effects*,  immunology*,  metabolism,  pathology
Drug Interactions
Humans
Lipopolysaccharides / metabolism,  pharmacology
Lymphocyte Activation / drug effects
NF-kappa B / metabolism
Neoplasms / drug therapy*,  immunology
Paclitaxel / pharmacology*
T-Lymphocytes / immunology
Tubulin / metabolism
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Cytokines; 0/Lipopolysaccharides; 0/NF-kappa B; 0/Tubulin; 33069-62-4/Paclitaxel; 64-86-8/Colchicine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  TGF-beta1 Induces Preferential Rapid Expansion and Persistence of Tumor Antigen-specific CD8+ T Cell...
Next Document:  Dendritic Cells Generated in Clinical Grade Bags Strongly Differ in Immune Functionality When Compar...